Using EIT to personalize PEEP during bariatric surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, single-blind randomized controlled trial will enroll 118 adults undergoing laparoscopic bariatric surgery and randomly assign them to EIT-guided individualized PEEP or a fixed PEEP of 8 cmH2O. The EIT group will have PEEP titrated based on bedside electrical impedance tomography imaging, while the control group will receive conventional lung-protective ventilation with fixed PEEP. The primary outcome is the incidence of postoperative pulmonary complications within 72 hours after surgery, with perioperative respiratory and hemodynamic parameters also recorded. The trial is being conducted at The First Affiliated Hospital of Shandong First Medical University in Jinan, China, with recruitment through the end of 2026.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 65 years;
2. Plan to receive laparoscopic bariatric surgery under general anesthesia;
3. American Society of Anaesthesiologists (ASA) physical status I-III;
4. BMI between 30 and 55 kg/m2;
5. Voluntary participation in this study and signing of an informed consent form.

Exclusion Criteria:

1. History of smoking or previous thoracic surgery;
2. Invasive mechanical ventilation within 30 days;
3. Pregnancy;
4. Allergy to EIT electrodes;
5. Persistent hemodynamic instability or refractory shock;
6. Severe cardiopulmonary disease (e.g., severe COPD (Chronic obstructive pulmonary disease), NYHA (New York Heart Association) Class III or IV, acute coronary syndrome, or sustained ventricular tachycardia);
7. Severe pulmonary hypertension (systolic pulmonary artery pressure \>40 mmHg);
8. Increased intracranial pressure, intracranial injury/tumor, or neuromuscular disorders;
9. Conversion to laparotomy;
10. Planned transfer to intensive care unit after surgery.

Where it's running

• The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
  Jinan, Shandong, China Recruiting

Study contacts

• Principal investigator: Na Guo, Ms. — Shandong First Medical University
• Study coordinator: Jian bo Wu, PH.D
• Email: jianbowu@126.com
• Phone: 18560083793

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Pulse Wave vs Saline Bolus EIT to measure lung perfusion in ARDS

  This study tests whether pulse wave EIT or saline bolus EIT can best show lung blood flow in ARDS patients on mechanical ventilation.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07908368

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.